Learning Objectives:

  1. To establish whether a reduced dose of rivaroxaban significantly decreased the composite outcome in patients on hemodialysis with atrial fibrillation.
  2. To determine clinical significance of study results.
Session date: 
05/21/2021 - 12:00pm to 1:00pm CDT
Zoom meeting
5700 S Maryland Ave
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Anand Narayanan, MD